<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1471">
  <stage>Registered</stage>
  <submitdate>18/07/2006</submitdate>
  <approvaldate>20/07/2006</approvaldate>
  <actrnumber>ACTRN12606000313538</actrnumber>
  <trial_identification>
    <studytitle>THE EFFECT OF ROSIGLITAZONE ON OXIDATIVE STRESS AND INSULIN RESISTANCE IN OVERWEIGHT INDIVIDUALS</studytitle>
    <scientifictitle>THE EFFECT OF ROSIGLITAZONE ON OXIDATIVE STRESS AND INSULIN RESISTANCE IN OVERWEIGHT INDIVIDUALS</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Rosiglitazone 4mg orally per day for 6 months.</interventions>
    <comparator>Placebo - identically matching capsule.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Oxidative stress markers</outcome>
      <timepoint>At 0, 3 and 6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Insulin Resistance</outcome>
      <timepoint>At 0, 3 and 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Inflammatory markers </outcome>
      <timepoint>0, 3 and 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Liver function </outcome>
      <timepoint>0, 3 and 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy individuals with BMI &gt; 27 kg/m2.</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Type 2 diabetes or known cardiovascular disease. Lipid lowering therapy, anti-inflammatory drugs, steroids. Recent surgery. Smoking.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>only one investigator privy to allocation and had no direct contact with participants.</concealment>
    <sequence>Computer generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/01/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>A/Prof PJ Manning</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Principal Investigator's research funds</fundingname>
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to determine whether  the drug rosiglitazone, commonly used for people with diabetes, when used in people who are overweight reduces the levels of markers of oxidative stress and improves the action of insulin.  If this was the case then this medication could potentially be considered for trials aimed at diabetes prevention.  This study will specifically look at the role of this drug in people with a body mass index (weight in relation to a persons height) of &gt;27kg/m2 (overweight).  Participants will be divided in to 2 groups, one will receive the active drug and the other a placebo.  At the end of the study a comparison will be made of the effectiveness of the drug compared to the placebo.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Dunedin Hospital-Otago Ethics Committee</ethicname>
      <ethicaddress>PO Box 5849, Dunedin, New Zealand</ethicaddress>
      <ethicapprovaldate>19/03/2003</ethicapprovaldate>
      <hrec>02/11/113</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Patrick Manning</name>
      <address>201 Great King Street
Dunedin</address>
      <phone>64 3 474 0999</phone>
      <fax />
      <email>PatrickManning@healthotago.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Patrick Manning</name>
      <address>Department of Endocrinology
Dunedin Hospital
201 Great King Street
Dunedin</address>
      <phone>64 3 474 0999</phone>
      <fax />
      <email>PatrickManning@healthotago.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>